Katharine Knobil - Nov 17, 2025 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Role
Director
Signature
/s/ Julio C. Esquivel as Attorney-In-Fact for Katharine Knobil
Stock symbol
MRKR
Transactions as of
Nov 17, 2025
Transactions value $
$0
Form type
4
Date filed
11/19/2025, 04:18 PM
Previous filing
Jun 12, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Knobil Katharine Director MARKER THERAPEUTICS, INC., 2450 HOLCOMBE BLVD, TMC PARTNERS OFFICE, HOUSTON /s/ Julio C. Esquivel as Attorney-In-Fact for Katharine Knobil 2025-11-19 0001768011

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRKR Stock Option (Right to Buy) Award $0 +84.4K $0.00 84.4K Nov 17, 2025 Common Stock 84.4K $0.95 Direct F1
transaction MRKR Stock Option (Right to Buy) Award $0 +137K $0.00 137K Nov 17, 2025 Common Stock 137K $0.95 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for the remaining options due as service as a director for the year 2024. 30,000 shares were previously granted on February 12, 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.
F2 Represents options granted under the Company's 2020 Omnibus Stock Ownership Plan for service as a director for the year 2025. The options vest on the anniversary of the grant date. The option exercise price is the closing price on the date of the grant, November 17, 2025.